Protons pump inhibitor treatment and lower gastrointestinal bleeding: Balancing risks and benefits
Resumen: Proton pump inhibitors (PPIs) represent a milestone in the treatment of acid-related diseases, and are the mainstay in preventing upper gastrointestinal bleeding in high-risk patients treated with nonsteroidal antiinflammatory drugs (NSAIDs) or low-dose aspirin. However, this beneficial effect does not extend to the lower gastrointestinal tract. PPIs do not prevent NSAID or aspirin-associated lower gastrointestinal bleeding (LGB). PPIs may increase both small bowel injury related to NSAIDs and low-dose aspirin treatment and the risk of LGB. Recent studies suggested that altering intestinal microbiota by PPIs may be involved in the pathogenesis of NSAID-enteropathy. An increase in LGB hospitalization rates may occur more frequently in older patients with more comorbidities and are associated with high hospital resource utilization, longer hospitalization, and increased mortality. Preventive strategies for NSAID and aspirin-associated gastrointestinal bleeding should be directed toward preventing both upper and lower gastrointestinal damage. Future research should be directed toward identifying patients at low-risk for gastrointestinal events associated with the use of NSAIDs or aspirin to avoid inappropriate PPI prescribing. Alternatively, the efficacy of new pharmacologic strategies should be evaluated in high-risk groups, with the aim of reducing the risk of both upper and lower gastrointestinal bleeding in these patients.
Idioma: Inglés
DOI: 10.3748/wjg.v22.i48.10477
Año: 2016
Publicado en: WORLD JOURNAL OF GASTROENTEROLOGY 22, 48 (2016), 10477-10481
ISSN: 1007-9327

Factor impacto JCR: 3.365 (2016)
Categ. JCR: GASTROENTEROLOGY & HEPATOLOGY rank: 29 / 79 = 0.367 (2016) - Q2 - T2
Factor impacto SCIMAGO: 1.272 - Medicine (miscellaneous) (Q1) - Gastroenterology (Q1)

Tipo y forma: Article (Published version)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)

Creative Commons You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Exportado de SIDERAL (2020-02-21-13:40:26)

Este artículo se encuentra en las siguientes colecciones:

 Record created 2017-03-27, last modified 2020-02-21

Versión publicada:
Rate this document:

Rate this document:
(Not yet reviewed)